Visudyne
(Verteporfin)ApprovedSmall molecule
Verteporfin is used to treat a type of age-related macular degeneration (a disease that causes vision loss in older people) by being injected into the bloodstream and then activated by a laser to destroy abnormal blood vessels in the eye.[2] Visudyne is currently approved and in use across 23 indications[4].[1]
Visudyne is one of 391 small molecule programs targeting Nevoid Basal Cell Carcinoma Syndrome. It is currently in Approved.
23
Indications
27
Total Trials
7
Active Trials
390
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 23 indications
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Zoladex
TTerSera Therapeutics LLC
Phase 3
Visudyne
BBausch Health Americas, Inc.
Approved
Androgen Deprivation Therapy
Johnson & JohnsonPhase 3
Orgovyx
Sumitomo Pharma America, Inc.Phase 3
Antibiotic
PfizerPhase 3
Perflutren Lipid Microspheres
SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 3
SHR3680
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Retinopathy3 trials
Pancreatic Cancer2 trials
AMD2 trials
17 more indications
Neovascular AMD1 trial
ESS1 trial
Polypoidal choroidal vasculopathy1 trial
Dexamethasone1 trial
Malignancies1 trial
Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies
Terminated·—·Phase 1·NCT02702700·1 enrolled
Airway obstruction1 trial
Brain Tumors1 trial
Prostate Cancer1 trial
Optical Coherence Tomography1 trial
Glioblastoma1 trial
Surgical1 trial
Unspecified1 trial
Lucentis KAV Study
Completed·TThe Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery·Phase 3·NCT01570608·51 enrolled
Regulatory
FDA Approval Timeline[5]
Apr 12, 2000
VISUDYNE
NDA NDA021119
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Visudyne drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Verteporfin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- BBausch Health Americas, Inc.